Last checked at 
LONDON (Alliance News) - ImmuPharma PLC shares were trading higher Wednesday morning after the company reported progress has been made on the phase III clinical trial of its Lupuzor lupus treatment.
ImmuPharma said the recruitment of the first patients to the study is due to start this year after the trial was approved by a major, unnamed Central Institutional Review Board which will allow several test sites to take part under a single agreement.
The first sites in the US are set to be initiated in late November or early December and will start recruiting patients thereafter.
The study is also making progress in Europe, with expectations the first sites will be initiated in January, with patient recruitment to start after that.
Tim McCarthy, ImmuPharma's chairman, commented: "Following my recent appointment as Chairman, I have now had the opportunity to review the progress of the Phase III study with both the ImmuPharma development team and Simbec-Orion. I am confident that given the dedication and expertise of the ImmuPharma team combined with the experience of Simbec-Orion, the study will progress as planned with the anticipation of completing the study by the end of 2017."
Shares in ImmuPharma were up 19% to 29.37 pence early Wednesday, one of the best performers in the AIM All-Share.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
